ATLAS fair value
$69.69
Close to fair value · 0% premium
TransMedics Group stock price today, ATLAS forecast and fair value
Healthcare · Medical Devices · NASDAQ
Prices as of Oct 27, 2026 · USD
$69.69
Close to fair value · 0% premium
49%
that it ends higher than today in 21 sessions
ATLAS's own quantitative analysis, all in one place.
Plans from €3.99 a month.
ATLAS estimates TransMedics Group's fair value at about $69.69 per share (reasonable range: $55.11 to $98.87). At $69.72, the stock trades within 8% of that figure: close to fair value.
It is calculated with a blend of a discounted cash-flow model and peer valuation multiples. Confidence in the estimate is medium. It is an estimate, not a promise: if the company's results change, so does its fair value.
ATLAS's model gives TransMedics Group a 49% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between $63.64 and $75.67; in 9 out of 10, between $54.58 and $88.22. Estimated annual volatility is 46%.
These are two different questions: fair value looks at the business (what it is worth given what it earns) and the odds look at the price over the next month. TransMedics Group sits close to fair value and its odds of rising over a month are close to a coin flip. An expensive stock can keep climbing and a cheap one can keep falling, which is why ATLAS shows the two readings separately.
Over the last 52 weeks TMDX has traded between $60.11 and $156.00. Today it is 55.3% below that high and 16% above its low.
On the business: revenue grew 37.1% year over year; net margin is 31.4%; it trades at 18.2 times earnings.
Its beta is 1.88: it tends to move more than the market, both up and down.
TransMedics Group, Inc. is a commercial-stage medical technology company focused on organ transplant therapy.
Want to see everything about TransMedics Group?
Get started →Plans from €3.99 a month.
Other companies in the same line of business:
About $69.69 per share according to ATLAS (reasonable range: $55.11 to $98.87). With the stock at $69.72, it is close to that value.
49%: close to a coin flip. In half of the simulated outcomes, TMDX ends the month between $63.64 and $75.67.
TransMedics Group's market capitalization is $2.8B. Its price-to-earnings (P/E) ratio is 18.2: you pay $18.2 for each $1 of yearly earnings.
ATLAS estimates annual volatility at 46%. In a typical month, half of the outcomes end between $63.64 and $75.67.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer
ATLAS Signals
The week in the market, three stocks on ATLAS’s radar and what comes next. Get it every Monday.
By subscribing you agree to receive ATLAS Signals by email every Monday. You can unsubscribe with one click at any time. Privacy